Welcome to Yaremenko Research Group, specializing in Nanomedicine and Biomedical Engineering!
❮ Aggregate ❯ ❮ Cover Paper ❯ Carbon Quantum Dots in Biomedical Applications: Advances, Challenges, and Future Prospects
❮ Advanced Functional Materials ❯ Implantable Biomaterials for Cancer Immunotherapies
❮ Aggregate ❯ Carbon Quantum Dots in Biomedical Applications: Advances, Challenges, and Future Prospects
❮ Aggregate ❯ Modification of contact lenses via metal-organic frameworks for glaucoma treatment
❮ Med ❯ Clinical advances of mRNA vaccines for cancer immunotherapy
❮ Journal of Nanobiotechnology ❯ Magnetogenetics as a promising tool for controlling cellular signaling pathways
❮ ACS Nano ❯ Long-Term Fate of Magnetic Particles in Mice: A Comprehensive Study
❮ Advanced Drug Delivery Reviews ❯ Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors
❮ Journal of Clinical Medicine ❯ Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon
❮ Nanoscale ❯Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth
Our Research Interests
Nanomedicine
Nanomedicine integrates nanoparticles, nanocarriers, and nanoscale biomaterials to revolutionize drug delivery, diagnostics, imaging, and regenerative medicine. Polymeric, lipid, metal, hybrid nanoparticles, and metal-organic frameworks are designed for targeted therapy, controlled drug release, and enhanced bioavailability while minimizing systemic toxicity. Applications extend to cancer treatment, glaucoma therapy, autoimmune disease management, ophthalmic drug delivery, etc.
Gene Therapy
Gene therapy employs mRNA, DNA, gene-editing technologies, and viral vectors to treat genetic and acquired diseases. Lipid nanoparticles, polymeric carriers, and viral/non-viral platforms enhance gene transfer efficiency and cellular uptake. Applications include cancer, retinal degeneration, and regenerative medicine, enabling precise genetic modulation. Advances in CRISPR, RNA interference (RNAi), and plasmid DNA delivery drive the future of gene editing and immunotherapy.
Cancer Bacteriotherapy
Cancer bacteriotherapy employs engineered bacteria to target tumors, modulate immunity, and deliver drugs or biomolecules. These bacteria, modified genetically, membranally, or intracellularly, thrive in hypoxic tumors, enabling selective drug release and immune activation. Beyond oncology, applications extend to metabolic disorders, microbiome modulation, and infectious treatment. Advances in synthetic biology, bacterial circuits, and biohybrid systems drive precision bacteriotherapy.
Research Overview
Our research is at the intersection of nanomedicine, gene therapy, biomaterials, cell engineering, and bacterial engineering, with a focus on developing innovative drug delivery systems and genetic therapeutics. We employ cutting-edge approaches to design and optimize nanoparticle-based platforms for the controlled and targeted delivery of therapeutic agents, including mRNA, DNA plasmids, proteins, and small molecules. Our goal is to enhance treatment efficacy while minimizing systemic toxicity, particularly in the fields of cancer therapy, regenerative medicine, and ophthalmic diseases.
Ongoing research includes:
Engineering multifunctional nanocarriers for the simultaneous delivery of genetic material and drugs, leveraging metal-organic frameworks, polymeric nanoparticles, and lipid-based systems.
Developing magnetically and enzymatically responsive drug release systems to enable precise, on-demand therapeutic delivery.
Advancing cell engineering strategies for targeted gene therapy, stem cell-based treatments, and regenerative medicine applications.
Harnessing bacterial engineering for innovative cancer bacteriotherapy, microbiome modulation, and targeted drug delivery.
Studying the interactions of nanoparticles with biological systems to understand biodistribution, clearance mechanisms, and immune responses.
Exploring next-generation mRNA therapeutics and immunotherapies for personalized medicine, with a focus on cancer treatment and vaccine development.
Developing ophthalmic drug delivery platforms, including novel contact lens-based systems for sustained drug release in glaucoma treatment.
Developing biomaterials for tissue regeneration, enhancing osteogenesis, and improving fracture healing through controlled drug and growth factor release, with a focus on applications using nanoparticle-engineered scaffolds to mimic physiological environments and promote tissue repair.
Our work integrates materials science, molecular biology, synthetic biology, and computational modeling to push the boundaries of precision medicine and biomedical innovation. Through interdisciplinary collaboration, we aim to translate our discoveries into real-world applications, improving patient outcomes and shaping the future of therapeutic nanotechnology.
Interested in Our Research? Let's Collaborate!
We welcome collaborations with researchers, biotech companies, and clinicians who share our passion for nanomedicine, gene therapy, biomaterials, bacterial engineering, and regenerative medicine. By working together, we can develop cutting-edge therapies, optimize drug delivery systems, and bring innovative biomedical solutions closer to patients. If you’re looking to join forces on groundbreaking research and real-world applications, let’s connect and explore the possibilities.
For collaboration opportunities, reach out to our Principal Investigator, Dr. Alexey V. Yaremenko, at dr.alex.yar@gmail.com. Let’s explore how we can drive innovation together!